Trial Profile

A Phase 2 Study to Evaluate Nasally Administered Foralumab for Progressive Multiple Sclerosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Foralumab (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Sponsors Tiziana Life Sciences

Most Recent Events

23 Aug 2023 According to a Tiziana Lifesciences media release, the company to conduct Phase 2a investigator's meeting, to announce 6-month clinical findings.
01 Jun 2022 According to a Tiziana Lifesciences media release, a recorded video of the KOL event discussing the topline data is available within the Investor/Presentations portion of the company website.
01 Jun 2022 According to a Tiziana Lifesciences media release, Dr. Tanuja Chitinis, MD will be presenting data from this study at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com